Lung Cancer Screening and Prevention Act of 2025
Introduced February 18, 2025 · Last action February 18, 2025
Plain English Summary
This bill expands Medicare coverage for lung cancer screening by allowing the Secretary of Health and Human Services to cover additional lung cancer screening tests beyond those currently covered, as long as the tests are approved by the FDA and furnished to appropriate individuals. The bill creates a new process for adding these tests to Medicare coverage without requiring certain economic evaluations normally required for other preventive services.
Who benefits
Medicare beneficiaries (age 65+ and some younger disabled individuals) who are eligible for lung cancer screening; healthcare providers and hospitals that deliver lung cancer screening services; diagnostic imaging companies and manufacturers of lung cancer screening devices (including companies producing low-dose CT, blood tests, and other FDA-cleared screening modalities); preventive medicine advocates and public health organizations focused on early cancer detection
Who pays / loses
The Medicare trust fund, which will incur costs for expanded screening coverage; Medicare taxpayers who fund the program; patients may lose modest cost-sharing protections if screening tests classified as preventive services later receive different cost-sharing designations, though preventive services typically carry no beneficiary cost-sharing
Funding & Lobbying Interests
Medical device manufacturers and diagnostic imaging companies with FDA-cleared or approved lung cancer screening products (including manufacturers of low-dose CT scanners, AI-enhanced screening platforms, and emerging blood-based biomarker tests) have a direct financial interest in expanded Medicare coverage. Lung cancer advocacy organizations and prevention-focused medical societies (such as those focused on oncology, radiology, and preventive medicine) support expanded screening access. The bill's sponsors include members from both parties; without detailed campaign finance data provided, the primary financial beneficiaries are device and diagnostic manufacturers who would gain revenue from increased Medicare reimbursement for new screening tests.
Political Impact
Affected Groups
Approximately 45 million Medicare beneficiaries age 65 and older, with heightened impact on current and former smokers (the target population for lung cancer screening); current smokers and former smokers account for roughly 34% of the U.S. adult population; rural Medicare beneficiaries who may have limited access to advanced screening facilities; healthcare systems and hospitals that perform preventive services; diagnostic imaging centers and ambulatory surgery centers offering screening services
Political Subtext
Proponents argue that expanded lung cancer screening coverage will enable earlier cancer detection, reduce mortality, and improve outcomes for high-risk populations—consistent with Medicare's preventive services expansion goals. They emphasize that FDA approval ensures safety and efficacy. Critics or skeptics may argue that the exemption from cost-effectiveness analysis (1861(ddd)(3)(B)) removes an important check on covering screening tests whose clinical benefit relative to cost may be uncertain, potentially leading to coverage of tests with marginal or unproven benefit-to-cost ratios. The bipartisan sponsorship suggests broad support for lung cancer prevention, though the substantive debate centers on whether the Secretary needs cost-effectiveness guardrails before adding new tests. Non-partisan research from entities like the U.S. Preventive Services Task Force has generally supported low-dose CT screening for high-risk smokers, but newer modalities (such as blood-based biomarkers) have emerging evidence that may not yet meet rigorous cost-benefit thresholds.
Real-World Stakes
If this passes, Medicare will begin covering new lung cancer screening tests as they receive FDA approval and the Secretary makes coverage determinations. This could accelerate adoption of emerging screening technologies (blood tests, advanced imaging) into clinical practice. Comparable expansions—such as Medicare's coverage of preventive colonoscopy (established in the mid-2000s) and more recent coverage of cardiovascular risk screening—show that Medicare preventive service expansion typically increases utilization and improves early detection rates, though the clinical and economic value depends heavily on the test's sensitivity, specificity, and cost. The removal of the cost-effectiveness evaluation requirement could lead to coverage of tests with uncertain or marginal cost-effectiveness, a pattern seen when Medicare covers services designated as 'preventive' without rigorous economic review. Historical precedent: Medicare's addition of preventive services under the Affordable Care Act (2010) without copayments expanded screening uptake significantly, particularly among lower-income beneficiaries, but some covered tests later faced scrutiny over clinical utility and cost. Without a fiscal impact statement in the bill, the precise cost to Medicare and beneficiaries remains unquantified.
Sponsor
Sponsor information not available.
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
No campaign finance data available yet.
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.